<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00863928</url>
  </required_header>
  <id_info>
    <org_study_id>IRB08100</org_study_id>
    <secondary_id>IRB08100</secondary_id>
    <nct_id>NCT00863928</nct_id>
  </id_info>
  <brief_title>Effects of Perioperative B&amp;O Suppositories on Post-op Pain and Morphine Use After Laparoscopic Prostatectomy</brief_title>
  <official_title>Effects of Perioperative Belladonna and Opium Suppositories on Postoperative Pain and Morphine Consumption on Patients After Robotic Assisted Laparoscopic Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benaroya Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Virginia Mason Hospital/Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Benaroya Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the effect of a Belladonna and Opium suppository administered
      intraoperatively on post operative pain after laparoscopic radical prostatectomy for prostate
      cancer. This is a blinded randomized study. 50% of patients will receive the suppository, 50%
      of patients will not. Neither you or your surgeon will know which group you are in.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients undergoing LRP at Virginia Mason Medical Center between November 1, 2008 and
      July 30, 2009 were offered the opportunity to participate in a randomized double blind
      clinical trial. Operating surgeons were blinded to suppository placement which was
      administered after induction of anesthesia. All patients underwent a standardized anesthesia
      regimen. Post-operative pain was assessed by a visual analog scale (VAS) and post-operative
      narcotic use was calculated in intravenous morphine equivalents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Assessment by Visual Analog Scale at Rest</measure>
    <time_frame>24 hours</time_frame>
    <description>The Pain Assessment by Visual Analog Scale (VAS) consists of 100 millimeter (mm) horizontal line with two endpoints 1-100, labeled &quot;no pain&quot; and &quot;worst possible pain. &quot;No pain&quot; is the minimum value and &quot;worst possible pain&quot; is the maximum value.
Minimum value or &quot;No Pain&quot; is considered a better outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No suppository given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B &amp; O suppository</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B &amp; O suppository, belladonna 16.2 mg and opium 60 mg suppository (Paddock Laboratories, Minneapolis, MN)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>belladonna 16.2 mg and opium 60 mg suppository</intervention_name>
    <description>belladonna 16.2 mg and opium 60 mg suppository</description>
    <arm_group_label>B &amp; O suppository</arm_group_label>
    <other_name>B &amp; O Suppository</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for laparoscopic radical prostatectomy at Virginia Mason, who do
             not have chronic pain or allergies to opioid analgesics are eligible for this study.

        Exclusion Criteria:

          -  Women are excluded due to the absence of a prostate.

          -  Children are excluded due to the absence of prostate cancer in this group.

          -  Patients meeting any of the following will not be eligible for the study:

               -  Patients at risk for complications from anticholinergic agents including those
                  with a history of glaucoma, bronchial asthma, convulsive disorder, or high risk
                  for delirium

               -  History of previous allergies or adverse reactions to belladonna and opium and/or
                  opioid analgesics

               -  History of chronic pain or chronic use of opioid and nonopioid analgesics

               -  History of alcohol or opioid dependency/abuse within last three months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Corman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benaroya Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <results_first_submitted>July 5, 2011</results_first_submitted>
  <results_first_submitted_qc>March 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2019</results_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benaroya Research Institute</investigator_affiliation>
    <investigator_full_name>John Corman, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>November 1, 2008 through July 30, 2009. Subjects recruited at medical center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>no intervention</description>
        </group>
        <group group_id="P2">
          <title>B &amp; O Suppository</title>
          <description>belladonna 16.2 mg and opium 60 mg suppository</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>surgery cancellation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>medication allergy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>no intervention</description>
        </group>
        <group group_id="B2">
          <title>B &amp; O Suppository</title>
          <description>belladonna 16.2 mg and opium 60 mg suppository</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="135"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.1" spread="6.86"/>
                    <measurement group_id="B2" value="62.7" spread="7"/>
                    <measurement group_id="B3" value="61.7" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Assessment by Visual Analog Scale at Rest</title>
        <description>The Pain Assessment by Visual Analog Scale (VAS) consists of 100 millimeter (mm) horizontal line with two endpoints 1-100, labeled &quot;no pain&quot; and &quot;worst possible pain. &quot;No pain&quot; is the minimum value and &quot;worst possible pain&quot; is the maximum value.
Minimum value or &quot;No Pain&quot; is considered a better outcome.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>no intervention</description>
          </group>
          <group group_id="O2">
            <title>B &amp; O Suppository</title>
            <description>belladonna 16.2 mg and opium 60 mg suppository</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Assessment by Visual Analog Scale at Rest</title>
          <description>The Pain Assessment by Visual Analog Scale (VAS) consists of 100 millimeter (mm) horizontal line with two endpoints 1-100, labeled &quot;no pain&quot; and &quot;worst possible pain. &quot;No pain&quot; is the minimum value and &quot;worst possible pain&quot; is the maximum value.
Minimum value or &quot;No Pain&quot; is considered a better outcome.</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.08" spread="18"/>
                    <measurement group_id="O2" value="13.84" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours post-operatively</time_frame>
      <desc>Sedation, nausea, and pruritis will be assessed by nursing every 1 hour x 4 hours, then every 2 hours by 4, then every 4 hours up to 24 hours post-op</desc>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>no intervention</description>
        </group>
        <group group_id="E2">
          <title>B &amp; O Suppository</title>
          <description>belladonna 16.2 mg and opium 60 mg suppository</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathryn Dahl, RN</name_or_title>
      <organization>Virginia Mason Medical Center</organization>
      <phone>206-341-0578</phone>
      <email>kathryn.dahl@vmmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

